"2962684"^^ . . "Kreuzprobe (Medizin)"@de . . "Bei Bluttransfusionen versteht man unter einer Kreuzprobe, korrekt eigentlich serologische Vertr\u00E4glichkeitsprobe, eine In-vitro-Untersuchung der Vertr\u00E4glichkeit von Spender- und Empf\u00E4ngerblut. Kreuzproben dienen dazu, Unvertr\u00E4glichkeiten aufgrund unterschiedlicher Blutgruppen auszuschlie\u00DFen. Dabei werden sowohl Unvertr\u00E4glichkeiten auf Grund der AB0-Blutgruppen als auch aus anderen Gr\u00FCnden, wie beispielsweise Rhesus-Unvertr\u00E4glichkeiten, ausgeschlossen.Nach der Vermischung kann makroskopisch und lichtmikroskopisch untersucht werden, ob eine Verklumpung (Agglutination) zustande kommt."@de . . . . . . . . "Bei Bluttransfusionen versteht man unter einer Kreuzprobe, korrekt eigentlich serologische Vertr\u00E4glichkeitsprobe, eine In-vitro-Untersuchung der Vertr\u00E4glichkeit von Spender- und Empf\u00E4ngerblut. Kreuzproben dienen dazu, Unvertr\u00E4glichkeiten aufgrund unterschiedlicher Blutgruppen auszuschlie\u00DFen. Dabei werden sowohl Unvertr\u00E4glichkeiten auf Grund der AB0-Blutgruppen als auch aus anderen Gr\u00FCnden, wie beispielsweise Rhesus-Unvertr\u00E4glichkeiten, ausgeschlossen.Nach der Vermischung kann makroskopisch und lichtmikroskopisch untersucht werden, ob eine Verklumpung (Agglutination) zustande kommt."@de . . . . "El cross-match o prueba cruzada es un estudio de histocompatibilidad que detecta la presencia de anticuerpos anti-HLA preformados en el suero de un paciente contra los linfocitos de un posible donante, con el fin de evitar la p\u00E9rdida inmediata del injerto.\u200B\u200B\u200B"@es . . . . . "Il cross-match o cross-matching \u00E8 parte della serie di passaggi dei test di compatibilit\u00E0 del sangue e dei tessuti, e consiste nel testare, prima di una trasfusione, se il sangue del donatore \u00E8 compatibile con il sangue del destinatario previsto, o anche per determinare la compatibilit\u00E0 nel trapianto di organi. La compatibilit\u00E0 \u00E8 determinata dall'abbinamento di diversi sistemi di gruppi sanguigni, i pi\u00F9 importanti dei quali sono il sistema AB0 e sistema Rh, e/o testando direttamente la presenza di anticorpi contro gli antigeni in un campione di sangue o di altri tessuti del donatore."@it . . . . . . . . "\u0627\u062E\u062A\u0628\u0627\u0631 \u0627\u0644\u062A\u0648\u0627\u0641\u0642 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Cross-matching)\u200F \u0641\u064A \u0627\u0644\u0637\u0628 \u064A\u0633\u062A\u062E\u062F\u0645 \u0647\u0630\u0627 \u0627\u0644\u0645\u0635\u0637\u0644\u062D \u0641\u064A \u0639\u0645\u0644\u064A\u0629 \u0646\u0642\u0644 \u0627\u0644\u062F\u0645. \u0648\u064A\u0634\u064A\u0631 \u0625\u0644\u0649 \u0627\u062E\u062A\u0628\u0627\u0631 \u0645\u0639\u0642\u062F \u064A\u062C\u0631\u0649 \u0644\u062F\u0645 \u0627\u0644\u0634\u062E\u0635 \u0627\u0644\u0645\u062A\u0628\u0631\u0639 \u0648\u0642\u0628\u0644 \u0625\u0639\u0637\u0627\u0626\u0647 \u0627\u0644\u0634\u062E\u0635 \u0627\u0644\u0645\u0633\u062A\u0641\u064A\u062F. \u0644\u062A\u062D\u062F\u064A\u062F \u0627\u0644\u062A\u0637\u0627\u0628\u0642 \u0628\u064A\u0646 \u0627\u0644\u0634\u062E\u0635\u064A\u0646 \u0641\u064A \u0641\u0635\u064A\u0644\u0629 \u0627\u0644\u062F\u0645. \u0623\u0648 \u0644\u062A\u062D\u062F\u064A\u062F \u0627\u0644\u062A\u0637\u0627\u0628\u0642 \u0641\u064A \u0639\u0645\u0644\u064A\u0629 \u0632\u0631\u0627\u0639\u0629 \u0627\u0644\u0623\u0639\u0636\u0627\u0621. \u0627\u062E\u062A\u0628\u0627\u0631 \u0627\u0644\u062A\u0648\u0627\u0641\u0642 \u064A\u062C\u0631\u0649 \u0639\u0627\u062F\u0629 \u0628\u0639\u062F \u0639\u062F\u0629 \u0627\u062E\u062A\u0628\u0627\u0631\u0627\u062A \u0623\u062E\u0631\u0649 \u0623\u0642\u0644 \u062A\u0639\u0642\u064A\u062F\u0627\u064B \u0644\u0643\u0646 \u0643\u0644 \u062A\u0644\u0643 \u0627\u0644\u0623\u062E\u062A\u0628\u0627\u0631\u0627\u062A \u0644\u064A\u0633\u062A \u062D\u0627\u0633\u0645\u0629 \u0628\u0646\u0633\u0628\u0629 \u0643\u0628\u064A\u0631\u0629. \u0646\u0638\u0631\u0627\u064B \u0644\u0623\u0646 \u0627\u0644\u062A\u0637\u0627\u0628\u0642 \u0641\u064A \u0627\u0644\u062F\u0645 \u0644\u064A\u0633 \u0641\u0642\u0637 \u0648\u0641\u0642\u0627\u064B \u0644\u0641\u0635\u0627\u0626\u0644 \u0627\u0644\u062F\u0645 \u0628\u0644 \u0647\u0646\u0627\u0643 \u0639\u062F\u0629 \u0639\u0648\u0627\u0645\u0644 \u0623\u062E\u0631\u0649 \u0643\u0646\u0638\u0627\u0645 RH \u060C \u0643\u064A\u0644 \u0648\u063A\u064A\u0631\u0647\u0645\u0627."@ar . . "Pr\u00F3ba krzy\u017Cowa, pr\u00F3ba zgodno\u015Bci - obowi\u0105zuj\u0105ca pr\u00F3ba przed ka\u017Cd\u0105 transfuzj\u0105 krwi, wykonywana w celu wykazania zgodno\u015Bci serologicznej mi\u0119dzy krwi\u0105 dawcy i biorcy w zakresie uk\u0142adu AB0 i Rh. Obejmuje: 1. \n* Badanie surowicy krwi biorcy wraz z krwinkami dawcy i surowicy dawcy z krwinkami biorcy w \u015Brodowisku fizjologicznego roztworu chlorku sodu. 2. \n* Kontrolne oznaczenie antygenu D z uk\u0142adu Rh w krwinkach biorcy w \u015Brodowisku papainy. Pr\u00F3b\u0119 krzy\u017Cow\u0105 ocenia si\u0119 jako zgodn\u0105, je\u017Celi w \u017Cadnym z przeprowadzonych nie wyst\u0105pi\u0142a aglutynacja lub hemoliza krwinek. Przy niezgodno\u015Bci pr\u00F3by krzy\u017Cowej, danej krwi nie mo\u017Cna przetoczy\u0107 danemu biorcy. Przeczytaj ostrze\u017Cenie dotycz\u0105ce informacji medycznych i pokrewnych zamieszczonych w Wikipedii."@pl . . "Cross-match"@it . . "Cross-matching"@en . "Prova cruzada"@pt . "Cross-matching or crossmatching is a test performed before a blood transfusion as part of blood compatibility testing. Normally, this involves adding the recipient's blood plasma to a sample of the donor's red blood cells. If the blood is incompatible, the antibodies in the recipient's plasma will bind to antigens on the donor red blood cells. This antibody-antigen reaction can be detected through visible clumping or destruction of the red blood cells, or by reaction with anti-human globulin. Along with blood typing of the donor and recipient and screening for unexpected blood group antibodies, cross-matching is one of a series of steps in pre-transfusion testing. In some circumstances, an electronic cross-match can be performed by comparing records of the recipient's ABO and Rh blood type against that of the donor sample. In emergencies, blood may be issued before cross-matching is complete. Cross-matching is also used to determine compatibility between a donor and recipient in organ transplantation."@en . . . . . . . "Compatibility testing concerning RBCs"@en . . "7228"^^ . "Cross-match"@es . . . . . . . . "Kruisproef"@nl . . . "Cross-matching"@en . "Prova cruzada \u00E9 um exame usado para testar, antes de uma transfus\u00E3o sangu\u00EDnea ou transplante de \u00F3rg\u00E3os, se o sangue do doador \u00E9 compat\u00EDvel com o sangue do receptor. A t\u00E9cnica que \u00E9 utilizada \u00E9 pegar o soro do receptor e colocar junto com linf\u00F3citos do doador com a finalidade de n\u00E3o ocorrer uma rejei\u00E7\u00E3o da parte do receptor, pois o paciente poder\u00E1 ter em seu organismo anticorpos contra os ant\u00EDgenos expressados na superf\u00EDcie das c\u00E9lulas do doador, podendo consequentemente causar rejei\u00E7\u00E3o."@pt . . . "El cross-match o prueba cruzada es un estudio de histocompatibilidad que detecta la presencia de anticuerpos anti-HLA preformados en el suero de un paciente contra los linfocitos de un posible donante, con el fin de evitar la p\u00E9rdida inmediata del injerto.\u200B\u200B\u200B"@es . "Bij de \"volledige\" kruisproef of de zogenoemde \u201CType en Screen-methode\u201D wordt de AB0-bloedgroep van pati\u00EBnt en donor met een in-vitrotest gecontroleerd, of moet de compatibiliteit van de AB0-bloedgroep door een \"korte\" kruisproef van pati\u00EBntenserum/plasma en in zoutoplossing worden gecontroleerd.Treedt hierbij samenklontering op (door aanwezigheid van antistoffen in een van beide sera gericht tegen cellen van de andere persoon) dan is bloedtransfusie niet mogelijk. Een volledige kruisproef (inclusief ) is altijd nodig bij: \n* pasgeborenen (tot de leeftijd van 3 maanden); er dient altijd (ook) gekruist te worden met het serum/plasma van de moeder; \n* pati\u00EBnten bij wie (ooit) klinisch relevante irregulaire erytrocytenantistoffen werden aangetoond; \n* ontvangers van orgaantransplantaten tot 3 maanden na transplantatie; \n* pati\u00EBnten na allogene stamceltransplantatie; \n* intra-uteriene transfusies; \n* pati\u00EBnten met aangeboren of verworven afwijkingen in de erytropo\u00EBse waarvoor frequent transfusies van erytrocyten moeten worden gegeven (bijvoorbeeld thalassemia major en (congenitale) hypoplastische anemie)."@nl . "Prova cruzada \u00E9 um exame usado para testar, antes de uma transfus\u00E3o sangu\u00EDnea ou transplante de \u00F3rg\u00E3os, se o sangue do doador \u00E9 compat\u00EDvel com o sangue do receptor. A t\u00E9cnica que \u00E9 utilizada \u00E9 pegar o soro do receptor e colocar junto com linf\u00F3citos do doador com a finalidade de n\u00E3o ocorrer uma rejei\u00E7\u00E3o da parte do receptor, pois o paciente poder\u00E1 ter em seu organismo anticorpos contra os ant\u00EDgenos expressados na superf\u00EDcie das c\u00E9lulas do doador, podendo consequentemente causar rejei\u00E7\u00E3o."@pt . . . . . "L'\u00E9preuve directe de compatibilit\u00E9 (EDC), encore appel\u00E9e cross-matching (\u00AB r\u00E9action crois\u00E9e \u00BB), est un examen de laboratoire qui consiste \u00E0 tester, dans les m\u00EAmes techniques que la recherche d'anticorps irr\u00E9guliers, le s\u00E9rum ou le plasma du malade vis-\u00E0-vis des concentr\u00E9s \u00E9rythrocytaires pr\u00E9vus pour sa transfusion. Ce test est long, et peut retarder une transfusion urgente. Il n'est donc pratiqu\u00E9, hors urgence, que chez les malades ayant, ou ayant eu, une recherche d'anticorps irr\u00E9guliers positive, ce qui est l\u00E9galement obligatoire, et parfois absurde dans ce dernier cas. En urgence, lorsque les anticorps sont identifi\u00E9s sans aucune ambig\u00FCit\u00E9, un sang dont le ph\u00E9notype est compatible avec le ph\u00E9notype du malade et les anticorps d\u00E9pist\u00E9s sera choisi. En France, une recherche d'anticorps irr\u00E9guliers n\u00E9gative est consid\u00E9r\u00E9e comme suffisante pour transfuser un patient. Ainsi, si un anticorps n\u2019avait pas \u00E9t\u00E9 d\u00E9pist\u00E9 ou identifi\u00E9 lors de la recherche d'anticorps irr\u00E9guliers, il pourra \u00EAtre mis en \u00E9vidence si l\u2019unit\u00E9 de sang pr\u00E9vue est incompatible, dans le cas o\u00F9 un premier anticorps en masque un second (anti-c masquant un anti-Jka par exemple, ce qui ne doit pas se voir, si on a pris soin de rajouter au panel 3 h\u00E9maties ph\u00E9notyp\u00E9es c- Jka+). D\u2019autres unit\u00E9s seront alors choisies, ph\u00E9notyp\u00E9es et test\u00E9es. Mais cette \u00E9preuve peut \u00EAtre illusoire. Lorsque l'anticorps d\u00E9pist\u00E9 n'est mis en \u00E9vidence que sur des h\u00E9maties homozygotes (anti-Fya ou anti-s ne sortant que sur des h\u00E9maties FY:1,-2 ou MNS:-3,4 par exemple), il ne reste, l'\u00E9preuve de compatibilit\u00E9 n'ayant pas de valeur pour s\u00E9lectionner les unit\u00E9s dans ce cas, que le choix d'unit\u00E9s ph\u00E9notyp\u00E9es pour transfuser le malade. L'\u00E9preuve directe de compatibilit\u00E9 permet parfois de mettre en \u00E9vidence une incompatibilit\u00E9 due \u00E0 un exceptionnel antig\u00E8ne priv\u00E9, antig\u00E8ne de groupe sanguin pr\u00E9sent sur les h\u00E9maties du donneur, l'anticorps pr\u00E9sent chez le receveur n'\u00E9tant que rarement d\u00E9pist\u00E9 \u00E0 l'occasion de la recherche d'anticorps irr\u00E9guliers. Ce test sera alors syst\u00E9matiquement pratiqu\u00E9 pour un receveur connu comme ayant un exceptionnel anticorps anti-priv\u00E9, anti MNS9 par exemple. Ces antig\u00E8nes priv\u00E9s rares ne sont pas recherch\u00E9s sur les dons de sang. Cette \u00E9preuve est recommand\u00E9e, mais non l\u00E9galement obligatoire, chez des patients transfus\u00E9s de fa\u00E7on it\u00E9rative -thalass\u00E9mie, Blackfan Diamond, dr\u00E9panocytose, d\u00E9ficit enzymatique, etc. En effet, ces patients sont transfus\u00E9s en sang ph\u00E9notyp\u00E9s dans de nombreux syst\u00E8mes en plus des syst\u00E8mes RH et KEL (ph\u00E9notype long : FY, JK, MNS...) et de ce fait ne sont transfus\u00E9s qu'\u00E0 partir d'un nombre tr\u00E8s limit\u00E9 de donneurs. D'o\u00F9 la plus grande probabilit\u00E9 d'apparition d'anticorps anti-priv\u00E9 et de r\u00E9actions transfusionnelles. \n* Portail de la m\u00E9decine \n* Portail de l\u2019h\u00E9matologie"@fr . "\u0627\u062E\u062A\u0628\u0627\u0631 \u0627\u0644\u062A\u0648\u0627\u0641\u0642 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Cross-matching)\u200F \u0641\u064A \u0627\u0644\u0637\u0628 \u064A\u0633\u062A\u062E\u062F\u0645 \u0647\u0630\u0627 \u0627\u0644\u0645\u0635\u0637\u0644\u062D \u0641\u064A \u0639\u0645\u0644\u064A\u0629 \u0646\u0642\u0644 \u0627\u0644\u062F\u0645. \u0648\u064A\u0634\u064A\u0631 \u0625\u0644\u0649 \u0627\u062E\u062A\u0628\u0627\u0631 \u0645\u0639\u0642\u062F \u064A\u062C\u0631\u0649 \u0644\u062F\u0645 \u0627\u0644\u0634\u062E\u0635 \u0627\u0644\u0645\u062A\u0628\u0631\u0639 \u0648\u0642\u0628\u0644 \u0625\u0639\u0637\u0627\u0626\u0647 \u0627\u0644\u0634\u062E\u0635 \u0627\u0644\u0645\u0633\u062A\u0641\u064A\u062F. \u0644\u062A\u062D\u062F\u064A\u062F \u0627\u0644\u062A\u0637\u0627\u0628\u0642 \u0628\u064A\u0646 \u0627\u0644\u0634\u062E\u0635\u064A\u0646 \u0641\u064A \u0641\u0635\u064A\u0644\u0629 \u0627\u0644\u062F\u0645. \u0623\u0648 \u0644\u062A\u062D\u062F\u064A\u062F \u0627\u0644\u062A\u0637\u0627\u0628\u0642 \u0641\u064A \u0639\u0645\u0644\u064A\u0629 \u0632\u0631\u0627\u0639\u0629 \u0627\u0644\u0623\u0639\u0636\u0627\u0621. \u0627\u062E\u062A\u0628\u0627\u0631 \u0627\u0644\u062A\u0648\u0627\u0641\u0642 \u064A\u062C\u0631\u0649 \u0639\u0627\u062F\u0629 \u0628\u0639\u062F \u0639\u062F\u0629 \u0627\u062E\u062A\u0628\u0627\u0631\u0627\u062A \u0623\u062E\u0631\u0649 \u0623\u0642\u0644 \u062A\u0639\u0642\u064A\u062F\u0627\u064B \u0644\u0643\u0646 \u0643\u0644 \u062A\u0644\u0643 \u0627\u0644\u0623\u062E\u062A\u0628\u0627\u0631\u0627\u062A \u0644\u064A\u0633\u062A \u062D\u0627\u0633\u0645\u0629 \u0628\u0646\u0633\u0628\u0629 \u0643\u0628\u064A\u0631\u0629. \u0646\u0638\u0631\u0627\u064B \u0644\u0623\u0646 \u0627\u0644\u062A\u0637\u0627\u0628\u0642 \u0641\u064A \u0627\u0644\u062F\u0645 \u0644\u064A\u0633 \u0641\u0642\u0637 \u0648\u0641\u0642\u0627\u064B \u0644\u0641\u0635\u0627\u0626\u0644 \u0627\u0644\u062F\u0645 \u0628\u0644 \u0647\u0646\u0627\u0643 \u0639\u062F\u0629 \u0639\u0648\u0627\u0645\u0644 \u0623\u062E\u0631\u0649 \u0643\u0646\u0638\u0627\u0645 RH \u060C \u0643\u064A\u0644 \u0648\u063A\u064A\u0631\u0647\u0645\u0627."@ar . . "Il cross-match o cross-matching \u00E8 parte della serie di passaggi dei test di compatibilit\u00E0 del sangue e dei tessuti, e consiste nel testare, prima di una trasfusione, se il sangue del donatore \u00E8 compatibile con il sangue del destinatario previsto, o anche per determinare la compatibilit\u00E0 nel trapianto di organi. La compatibilit\u00E0 \u00E8 determinata dall'abbinamento di diversi sistemi di gruppi sanguigni, i pi\u00F9 importanti dei quali sono il sistema AB0 e sistema Rh, e/o testando direttamente la presenza di anticorpi contro gli antigeni in un campione di sangue o di altri tessuti del donatore. In medicina trasfusionale il siero del paziente viene testato con i globuli rossi del donatore per accertarsi dell\u2019assenza di reazioni immunitarie. In chirurgia dei trapianti si pongono a contatto i linfociti del donatore con il siero del ricevente, valutando la presenza di anticorpi contro gli antigeni HLA del donatore, condizione che pu\u00F2 essere stata causata da precedenti trasfusioni, trapianti o gravidanze. Il cross-match viene eseguito da un tecnico di laboratorio. Pu\u00F2 essere fatto elettronicamente con un database se un paziente \u00E8 stato precedentemente testato, oppure sierologicamente mediante test fisici. I test pi\u00F9 semplici possono essere utilizzati per determinare solo il gruppo sanguigno o per selezionare solo gli anticorpi (test di Coombs indiretto)."@it . . . . . . . "L'\u00E9preuve directe de compatibilit\u00E9 (EDC), encore appel\u00E9e cross-matching (\u00AB r\u00E9action crois\u00E9e \u00BB), est un examen de laboratoire qui consiste \u00E0 tester, dans les m\u00EAmes techniques que la recherche d'anticorps irr\u00E9guliers, le s\u00E9rum ou le plasma du malade vis-\u00E0-vis des concentr\u00E9s \u00E9rythrocytaires pr\u00E9vus pour sa transfusion. Ce test est long, et peut retarder une transfusion urgente. Il n'est donc pratiqu\u00E9, hors urgence, que chez les malades ayant, ou ayant eu, une recherche d'anticorps irr\u00E9guliers positive, ce qui est l\u00E9galement obligatoire, et parfois absurde dans ce dernier cas. En urgence, lorsque les anticorps sont identifi\u00E9s sans aucune ambig\u00FCit\u00E9, un sang dont le ph\u00E9notype est compatible avec le ph\u00E9notype du malade et les anticorps d\u00E9pist\u00E9s sera choisi. En France, une recherche d'anticorps irr"@fr . "\u4EA4\u5DEE\u9069\u5408\u8A66\u9A13\uFF08\u3053\u3046\u3055\u3066\u304D\u3054\u3046\u3057\u3051\u3093\uFF09\u306F\u8F38\u8840\u306B\u4F34\u3046\u526F\u4F5C\u7528\u3092\u9632\u6B62\u3059\u308B\u305F\u3081\u306B\u884C\u308F\u308C\u308B\u691C\u67FB\u3067\u3042\u308B\u3002\u30AF\u30ED\u30B9\u30DE\u30C3\u30C1\u30C6\u30B9\u30C8 (cross-match test) \u3068\u3082\u3044\u3046\u3002\u53D7\u8840\u8005\uFF08\u60A3\u8005\uFF09\u306E\u8840\u6DB2\u3068\u4F9B\u8840\u8005\uFF08\u30C9\u30CA\u30FC\uFF09\u306E\u8840\u6DB2\u3092\u6DF7\u5408\u3057\u3066\u53CD\u5FDC\u306E\u6709\u7121\u3092\u307F\u308B\u3082\u306E\u3067\u3001ABO\u5F0F\u8840\u6DB2\u578B\u306E\u4E0D\u9069\u5408\u3084\u3001\u305D\u306E\u4ED6\u306E\u8840\u6DB2\u578B\u306B\u5BFE\u3059\u308B\u514D\u75AB\u6297\u4F53 (IgG)\u3092\u691C\u51FA\u3067\u304D\u308B\u65B9\u6CD5\u3092\u7528\u3044\u308B\u5FC5\u8981\u304C\u3042\u308B\u3002 \u4EA4\u5DEE\u9069\u5408\u8A66\u9A13\u306B\u306F\u3001\u53D7\u8840\u8005\u8840\u6E05\u4E2D\u306B\u4F9B\u8840\u8005\u8840\u7403\u306B\u5BFE\u3059\u308B\u6297\u4F53\u304C\u3042\u308B\u304B\u3069\u3046\u304B\u3092\u8ABF\u3079\u308B\u4E3B\u8A66\u9A13\u3068\u3001\u4F9B\u8840\u8005\u8840\u6E05\u4E2D\u306B\u53D7\u8840\u8005\u8840\u7403\u306B\u5BFE\u3059\u308B\u6297\u4F53\u304C\u3042\u308B\u304B\u3069\u3046\u304B\u3092\u8ABF\u3079\u308B\u526F\u8A66\u9A13\u304C\u3042\u308B\u3002\u3053\u306E\u3046\u3061\u526F\u8A66\u9A13\u306F\u3001\u53D7\u8840\u8005\u306E\u8840\u6DB2\u578B\u3001\u4F9B\u8840\u306E\u8840\u6DB2\u578B\u53CA\u3073\u4E0D\u898F\u5247\u6297\u4F53\u306E\u691C\u67FB\u304C\u6B63\u3057\u304F\u884C\u308F\u308C\u3066\u3044\u308B\u5834\u5408\u306B\u306F\u7701\u7565\u3059\u308B\u3053\u3068\u304C\u3067\u304D\u308B\u3002 \u8A66\u9A13\u306E\u7D50\u679C\u3001\u9670\u6027\uFF08\u53CD\u5FDC\u306A\u3057\uFF09\u3067\u3042\u308C\u3070\u8F38\u8840\u304C\u53EF\u80FD\u3067\u3042\u308B\u3002\u967D\u6027\u3001\u3059\u306A\u308F\u3061\u51DD\u96C6\u307E\u305F\u306F\u6EB6\u8840\u53CD\u5FDC\u304C\u78BA\u8A8D\u3055\u308C\u308C\u3070\u6297\u4F53\u304C\u5B58\u5728\u3059\u308B\u3053\u3068\u3092\u610F\u5473\u3059\u308B\u3002\u3053\u306E\u5834\u5408\u3001\u4F9B\u8840\u8005\u8840\u6DB2\u304C\u53D7\u8840\u8005\u4F53\u5185\u306B\u5165\u308B\u3053\u3068\u306B\u3088\u308A\u514D\u75AB\u53CD\u5FDC\u304C\u8D77\u3053\u308B\u305F\u3081\u3001\u539F\u5247\u3068\u3057\u3066\u8F38\u8840\u3092\u884C\u3046\u3053\u3068\u306F\u3067\u304D\u306A\u3044\u3002 \u4E3B\u8A66\u9A13\u3068\u526F\u8A66\u9A13\u306E\u7D50\u679C\u304C\u5408\u81F4\u3057\u306A\u304B\u3063\u305F\u5834\u5408\u306F\u4ED6\u306E\u8840\u6DB2\u3092\u4F7F\u7528\u3059\u308B\u3053\u3068\u304C\u671B\u307E\u3057\u3044\u304C\u3001\u7DCA\u6025\u6642\u306B\u306F\u4E3B\u8A66\u9A13\u306E\u5224\u5B9A\u3092\u512A\u5148\u3059\u308B\u3002 \u307E\u305F\u3001\u300C\u30A4\u30CC\u306F\u3092\u4FDD\u6709\u3057\u306A\u3044\u306E\u3067\u3001\u4F9B\u8840\u72AC\u3001\u53D7\u8840\u72AC\u4E21\u8005\u304C\u732E\u8840\u7D4C\u9A13\u3092\u6301\u305F\u306A\u3044\u5834\u5408\u306F\u4EA4\u5DEE\u9069\u5408\u8A66\u9A13\u306E\u5FC5\u8981\u306F\u306A\u3044\u300D\u3068\u4FE1\u3058\u3089\u308C\u3001\u30DE\u30C3\u30C1\u30F3\u30B0\u306E\u78BA\u8A8D\u3092\u305B\u305A\u306B\u8F38\u8840\u3059\u308B\u3088\u3046\u306A\u8352\u7642\u6CBB\u3092\u884C\u3046\u7363\u533B\u3082\u3044\u305F\u304C\u3001\u5B9F\u306F\u8AA4\u308A\u3067\u3042\u308B\u3002"@ja . "\u4EA4\u5DEE\u9069\u5408\u8A66\u9A13\uFF08\u3053\u3046\u3055\u3066\u304D\u3054\u3046\u3057\u3051\u3093\uFF09\u306F\u8F38\u8840\u306B\u4F34\u3046\u526F\u4F5C\u7528\u3092\u9632\u6B62\u3059\u308B\u305F\u3081\u306B\u884C\u308F\u308C\u308B\u691C\u67FB\u3067\u3042\u308B\u3002\u30AF\u30ED\u30B9\u30DE\u30C3\u30C1\u30C6\u30B9\u30C8 (cross-match test) \u3068\u3082\u3044\u3046\u3002\u53D7\u8840\u8005\uFF08\u60A3\u8005\uFF09\u306E\u8840\u6DB2\u3068\u4F9B\u8840\u8005\uFF08\u30C9\u30CA\u30FC\uFF09\u306E\u8840\u6DB2\u3092\u6DF7\u5408\u3057\u3066\u53CD\u5FDC\u306E\u6709\u7121\u3092\u307F\u308B\u3082\u306E\u3067\u3001ABO\u5F0F\u8840\u6DB2\u578B\u306E\u4E0D\u9069\u5408\u3084\u3001\u305D\u306E\u4ED6\u306E\u8840\u6DB2\u578B\u306B\u5BFE\u3059\u308B\u514D\u75AB\u6297\u4F53 (IgG)\u3092\u691C\u51FA\u3067\u304D\u308B\u65B9\u6CD5\u3092\u7528\u3044\u308B\u5FC5\u8981\u304C\u3042\u308B\u3002 \u4EA4\u5DEE\u9069\u5408\u8A66\u9A13\u306B\u306F\u3001\u53D7\u8840\u8005\u8840\u6E05\u4E2D\u306B\u4F9B\u8840\u8005\u8840\u7403\u306B\u5BFE\u3059\u308B\u6297\u4F53\u304C\u3042\u308B\u304B\u3069\u3046\u304B\u3092\u8ABF\u3079\u308B\u4E3B\u8A66\u9A13\u3068\u3001\u4F9B\u8840\u8005\u8840\u6E05\u4E2D\u306B\u53D7\u8840\u8005\u8840\u7403\u306B\u5BFE\u3059\u308B\u6297\u4F53\u304C\u3042\u308B\u304B\u3069\u3046\u304B\u3092\u8ABF\u3079\u308B\u526F\u8A66\u9A13\u304C\u3042\u308B\u3002\u3053\u306E\u3046\u3061\u526F\u8A66\u9A13\u306F\u3001\u53D7\u8840\u8005\u306E\u8840\u6DB2\u578B\u3001\u4F9B\u8840\u306E\u8840\u6DB2\u578B\u53CA\u3073\u4E0D\u898F\u5247\u6297\u4F53\u306E\u691C\u67FB\u304C\u6B63\u3057\u304F\u884C\u308F\u308C\u3066\u3044\u308B\u5834\u5408\u306B\u306F\u7701\u7565\u3059\u308B\u3053\u3068\u304C\u3067\u304D\u308B\u3002 \u8A66\u9A13\u306E\u7D50\u679C\u3001\u9670\u6027\uFF08\u53CD\u5FDC\u306A\u3057\uFF09\u3067\u3042\u308C\u3070\u8F38\u8840\u304C\u53EF\u80FD\u3067\u3042\u308B\u3002\u967D\u6027\u3001\u3059\u306A\u308F\u3061\u51DD\u96C6\u307E\u305F\u306F\u6EB6\u8840\u53CD\u5FDC\u304C\u78BA\u8A8D\u3055\u308C\u308C\u3070\u6297\u4F53\u304C\u5B58\u5728\u3059\u308B\u3053\u3068\u3092\u610F\u5473\u3059\u308B\u3002\u3053\u306E\u5834\u5408\u3001\u4F9B\u8840\u8005\u8840\u6DB2\u304C\u53D7\u8840\u8005\u4F53\u5185\u306B\u5165\u308B\u3053\u3068\u306B\u3088\u308A\u514D\u75AB\u53CD\u5FDC\u304C\u8D77\u3053\u308B\u305F\u3081\u3001\u539F\u5247\u3068\u3057\u3066\u8F38\u8840\u3092\u884C\u3046\u3053\u3068\u306F\u3067\u304D\u306A\u3044\u3002 \u4E3B\u8A66\u9A13\u3068\u526F\u8A66\u9A13\u306E\u7D50\u679C\u304C\u5408\u81F4\u3057\u306A\u304B\u3063\u305F\u5834\u5408\u306F\u4ED6\u306E\u8840\u6DB2\u3092\u4F7F\u7528\u3059\u308B\u3053\u3068\u304C\u671B\u307E\u3057\u3044\u304C\u3001\u7DCA\u6025\u6642\u306B\u306F\u4E3B\u8A66\u9A13\u306E\u5224\u5B9A\u3092\u512A\u5148\u3059\u308B\u3002 \u307E\u305F\u3001\u300C\u30A4\u30CC\u306F\u3092\u4FDD\u6709\u3057\u306A\u3044\u306E\u3067\u3001\u4F9B\u8840\u72AC\u3001\u53D7\u8840\u72AC\u4E21\u8005\u304C\u732E\u8840\u7D4C\u9A13\u3092\u6301\u305F\u306A\u3044\u5834\u5408\u306F\u4EA4\u5DEE\u9069\u5408\u8A66\u9A13\u306E\u5FC5\u8981\u306F\u306A\u3044\u300D\u3068\u4FE1\u3058\u3089\u308C\u3001\u30DE\u30C3\u30C1\u30F3\u30B0\u306E\u78BA\u8A8D\u3092\u305B\u305A\u306B\u8F38\u8840\u3059\u308B\u3088\u3046\u306A\u8352\u7642\u6CBB\u3092\u884C\u3046\u7363\u533B\u3082\u3044\u305F\u304C\u3001\u5B9F\u306F\u8AA4\u308A\u3067\u3042\u308B\u3002"@ja . . "\u00C9preuve directe de compatibilit\u00E9"@fr . "1097518504"^^ . "Pr\u00F3ba krzy\u017Cowa"@pl . "D001788"@en . . . . "\u4EA4\u5DEE\u9069\u5408\u8A66\u9A13"@ja . "Bij de \"volledige\" kruisproef of de zogenoemde \u201CType en Screen-methode\u201D wordt de AB0-bloedgroep van pati\u00EBnt en donor met een in-vitrotest gecontroleerd, of moet de compatibiliteit van de AB0-bloedgroep door een \"korte\" kruisproef van pati\u00EBntenserum/plasma en in zoutoplossing worden gecontroleerd.Treedt hierbij samenklontering op (door aanwezigheid van antistoffen in een van beide sera gericht tegen cellen van de andere persoon) dan is bloedtransfusie niet mogelijk. Een volledige kruisproef (inclusief ) is altijd nodig bij:"@nl . . . "Pr\u00F3ba krzy\u017Cowa, pr\u00F3ba zgodno\u015Bci - obowi\u0105zuj\u0105ca pr\u00F3ba przed ka\u017Cd\u0105 transfuzj\u0105 krwi, wykonywana w celu wykazania zgodno\u015Bci serologicznej mi\u0119dzy krwi\u0105 dawcy i biorcy w zakresie uk\u0142adu AB0 i Rh. Obejmuje: 1. \n* Badanie surowicy krwi biorcy wraz z krwinkami dawcy i surowicy dawcy z krwinkami biorcy w \u015Brodowisku fizjologicznego roztworu chlorku sodu. 2. \n* Kontrolne oznaczenie antygenu D z uk\u0142adu Rh w krwinkach biorcy w \u015Brodowisku papainy. Przeczytaj ostrze\u017Cenie dotycz\u0105ce informacji medycznych i pokrewnych zamieszczonych w Wikipedii."@pl . . . "Cross-matching or crossmatching is a test performed before a blood transfusion as part of blood compatibility testing. Normally, this involves adding the recipient's blood plasma to a sample of the donor's red blood cells. If the blood is incompatible, the antibodies in the recipient's plasma will bind to antigens on the donor red blood cells. This antibody-antigen reaction can be detected through visible clumping or destruction of the red blood cells, or by reaction with anti-human globulin. Along with blood typing of the donor and recipient and screening for unexpected blood group antibodies, cross-matching is one of a series of steps in pre-transfusion testing. In some circumstances, an electronic cross-match can be performed by comparing records of the recipient's ABO and Rh blood type"@en . . "\u0627\u062E\u062A\u0628\u0627\u0631 \u0627\u0644\u062A\u0648\u0627\u0641\u0642"@ar . . . . . .